Erika F H Saunders1, Dahlia Mukherjee1, Tiffany Myers1, Emily Wasserman2, Ahmad Hameed1, Venkatesh Bassappa Krishnamurthy1, Beth MacIntosh3, Anthony Domenichiello4, Christopher E Ramsden4,5, Ming Wang2. 1. Department of Psychiatry and Behavioral Health, Penn State University College of Medicine, Hershey, PA, USA. 2. Department of Public Health Sciences, Penn State University College of Medicine, Hershey, PA, USA. 3. Metabolic and Nutrition Research Core, University of North Carolina, Chapel Hill, NC, USA. 4. National Institute on Aging, National Institutes of Health, Baltimore, MD, USA. 5. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
Abstract
OBJECTIVE: To investigate the preliminary efficacy of a high n-3 plus low n-6 (H3-L6) dietary intervention in improving mood stability in Bipolar Disorder (BD) when compared to dietary intervention with usual U.S. levels of n-6 and n-3 polyunsaturated fatty acid (PUFA) intakes (control diet, CD). METHODS: This 2-arm, parallel-group, randomized, modified double-blind, controlled 48-week study of 12-week intensive diet intervention in subjects with BD was conducted at a single suburban-rural site in the mid-Atlantic region. Participants with DSM-IV TR BD I or II with hypomanic or depressive symptoms were randomized, stratified on gender (N = 82). The intervention included the provision of group-specific study foods and dietary counseling. Variability of mood symptoms was measured by a twice-daily, 12-week ecological momentary analysis (EMA) paradigm, and group differences were analyzed using multilevel models. Circulating n-3 and n-6 fatty acids were measured at baseline and after 4, 8, and 12 weeks of diet exposure. RESULTS: All 82 randomized participants were included in biochemical analyses. Seventy participants completed at least 2 EMA surveys and were included in primary EMA analyses. Variability in mood, energy, irritability, and pain as measured using EMA was reduced in the H3-L6 group compared to the CD group. No significant differences in mean ratings of mood symptoms, or any other symptom measures, were detected. The dietary intervention effect on target PUFAs significantly differed by the group over time. CONCLUSIONS: A dietary intervention adjunctive to usual care showed preliminary efficacy in improving variability in mood symptoms in participants with BD. TRIAL REGISTRATION: ClinicalTrials.Gov NCT02272010.
OBJECTIVE: To investigate the preliminary efficacy of a high n-3 plus low n-6 (H3-L6) dietary intervention in improving mood stability in Bipolar Disorder (BD) when compared to dietary intervention with usual U.S. levels of n-6 and n-3 polyunsaturated fatty acid (PUFA) intakes (control diet, CD). METHODS: This 2-arm, parallel-group, randomized, modified double-blind, controlled 48-week study of 12-week intensive diet intervention in subjects with BD was conducted at a single suburban-rural site in the mid-Atlantic region. Participants with DSM-IV TR BD I or II with hypomanic or depressive symptoms were randomized, stratified on gender (N = 82). The intervention included the provision of group-specific study foods and dietary counseling. Variability of mood symptoms was measured by a twice-daily, 12-week ecological momentary analysis (EMA) paradigm, and group differences were analyzed using multilevel models. Circulating n-3 and n-6 fatty acids were measured at baseline and after 4, 8, and 12 weeks of diet exposure. RESULTS: All 82 randomized participants were included in biochemical analyses. Seventy participants completed at least 2 EMA surveys and were included in primary EMA analyses. Variability in mood, energy, irritability, and pain as measured using EMA was reduced in the H3-L6 group compared to the CD group. No significant differences in mean ratings of mood symptoms, or any other symptom measures, were detected. The dietary intervention effect on target PUFAs significantly differed by the group over time. CONCLUSIONS: A dietary intervention adjunctive to usual care showed preliminary efficacy in improving variability in mood symptoms in participants with BD. TRIAL REGISTRATION: ClinicalTrials.Gov NCT02272010.
Authors: Paul E Keck; Jim Mintz; Susan L McElroy; Marlene P Freeman; Trisha Suppes; Mark A Frye; Lori L Altshuler; Ralph Kupka; Willem A Nolen; Gabriele S Leverich; Kirk D Denicoff; Heinz Grunze; Naihua Duan; Robert M Post Journal: Biol Psychiatry Date: 2006-06-30 Impact factor: 13.382
Authors: Daniela V Bavaresco; Tamy Colonetti; Antônio J Grande; Francesc Colom; Samira S Valvassori; João Quevedo; Maria I da Rosa Journal: CNS Neurol Disord Drug Targets Date: 2019 Impact factor: 4.388
Authors: Erika F H Saunders; Christopher E Ramsden; Mostafa S Sherazy; Alan J Gelenberg; John M Davis; Stanley I Rapoport Journal: J Clin Psychiatry Date: 2016-10 Impact factor: 4.384
Authors: Edmund A Reese; Yewon Cheon; Epolia Ramadan; Hyung-Wook Kim; Lisa Chang; Jagadeesh S Rao; Stanley I Rapoport; Ameer Y Taha Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2012-07-27 Impact factor: 4.006
Authors: Kathleen R Merikangas; Hagop S Akiskal; Jules Angst; Paul E Greenberg; Robert M A Hirschfeld; Maria Petukhova; Ronald C Kessler Journal: Arch Gen Psychiatry Date: 2007-05
Authors: Beth L Murphy; Andrew L Stoll; Peter Q Harris; Caitlin Ravichandran; Suzann M Babb; William A Carlezon; Bruce M Cohen Journal: J Clin Psychopharmacol Date: 2012-10 Impact factor: 3.153
Authors: Hiren R Modi; Ameer Y Taha; Hyung-Wook Kim; Lisa Chang; Stanley I Rapoport; Yewon Cheon Journal: J Neurochem Date: 2012-12-06 Impact factor: 5.372